Data from 2 studies, LIGHTHOUSE and SPOTLIGHT, have shown the benefit of flotufolastat F 18 injection as a radiohybrid PSMA-targeted PET imaging agent in prostate cancer. The agent has now been added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology.
NCCN Adds Flotufolastat F 18 Injection to Clinical Practice Guidelines for Prostate Cancer onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.
- Clinical utility of 18F-fluciclovine being investigated in expanded areas of cancer imaging - Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization